...
search icon
chrs-img

Coherus BioSciences Inc, Common Stock

CHRS

NMQ

$1.03

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$122.85M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
4.12
Volume info-icon
This is the total number of shares traded during the most recent trading day.
1.64M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.01
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.66 L
$2.43 H
$1.03

About Coherus BioSciences Inc, Common Stock

Coherus BioSciences, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 monoclonal antibody, a chemokine receptor highly expressed on Treg cells in the tumor microenvironment (TME); and CHS-1000, Anti-ILT4 monoclonal antibody for solid tumors. In addition, the company offers GSK4381562, an antibody targeting CD112R to treat tumor cells; YUSIMRY, a biosimilar to Humira for inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis; and CIMERLI, a Lucentis biosimilar to treat neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization. It has a collaboration agreement with Junshi Biosciences for the co-development and commercialization of toripalimab; agreement with Surface and Adimab LLC; license agreements with Bioeq AG and Genentech, Inc. and Surface and Vaccinex, Inc.; and out-licensing agreement with Novartis Institutes for Biomedical Research, Inc. and GlaxoSmithKline Intellectual Property No. 4 Limited. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. The company was incorporated in 2010 and is based in Redwood City, California. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameCHRSSectorS&P500
1-Week Return-2.83%4.13%7.14%
1-Month Return22.82%-4.48%-0.92%
3-Month Return-7.21%-5.78%-8.95%
6-Month Return42.76%-7.23%-5.21%
1-Year Return-50.24%-1.69%7.95%
3-Year Return-89.08%3.23%28.74%
5-Year Return-93.93%38.7%92.67%
10-Year Return-95.25%88.08%161.14%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue475.82M326.55M211.04M257.24M266.96M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":68.63,"profit":true},{"date":"2022-12-31","value":44.35,"profit":true},{"date":"2023-12-31","value":54.06,"profit":true},{"date":"2024-12-31","value":56.1,"profit":true}]
Cost of Revenue37.67M57.59M70.08M162.78M117.55M[{"date":"2020-12-31","value":23.14,"profit":true},{"date":"2021-12-31","value":35.38,"profit":true},{"date":"2022-12-31","value":43.05,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":72.21,"profit":true}]
Gross Profit438.16M268.96M140.96M94.46M149.41M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":61.38,"profit":true},{"date":"2022-12-31","value":32.17,"profit":true},{"date":"2023-12-31","value":21.56,"profit":true},{"date":"2024-12-31","value":34.1,"profit":true}]
Gross Margin92.08%82.36%66.79%36.72%55.97%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":89.44,"profit":true},{"date":"2022-12-31","value":72.53,"profit":true},{"date":"2023-12-31","value":39.88,"profit":true},{"date":"2024-12-31","value":60.78,"profit":true}]
Operating Expenses281.84M532.82M397.84M301.45M261.07M[{"date":"2020-12-31","value":52.9,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.67,"profit":true},{"date":"2023-12-31","value":56.58,"profit":true},{"date":"2024-12-31","value":49,"profit":true}]
Operating Income156.32M(263.86M)(256.88M)(203.20M)(111.67M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-168.79,"profit":false},{"date":"2022-12-31","value":-164.33,"profit":false},{"date":"2023-12-31","value":-129.99,"profit":false},{"date":"2024-12-31","value":-71.44,"profit":false}]
Total Non-Operating Income/Expense(41.78M)(46.20M)(67.35M)(75.61M)113.02M[{"date":"2020-12-31","value":-36.97,"profit":false},{"date":"2021-12-31","value":-40.88,"profit":false},{"date":"2022-12-31","value":-59.59,"profit":false},{"date":"2023-12-31","value":-66.91,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income135.71M(287.10M)(291.75M)(238.27M)28.51M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-211.56,"profit":false},{"date":"2022-12-31","value":-214.99,"profit":false},{"date":"2023-12-31","value":-175.58,"profit":false},{"date":"2024-12-31","value":21.01,"profit":true}]
Income Taxes3.46M19.22M34.87M(380.00K)28.51M[{"date":"2020-12-31","value":9.93,"profit":true},{"date":"2021-12-31","value":55.12,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-1.09,"profit":false},{"date":"2024-12-31","value":81.74,"profit":true}]
Income After Taxes132.24M(306.32M)(326.63M)(237.89M)-[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-231.63,"profit":false},{"date":"2022-12-31","value":-246.99,"profit":false},{"date":"2023-12-31","value":-179.89,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations132.24M(287.10M)(291.75M)(237.89M)28.51M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-217.1,"profit":false},{"date":"2022-12-31","value":-220.62,"profit":false},{"date":"2023-12-31","value":-179.89,"profit":false},{"date":"2024-12-31","value":21.56,"profit":true}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income132.24M(306.32M)(326.63M)(237.89M)28.51M[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-231.63,"profit":false},{"date":"2022-12-31","value":-246.99,"profit":false},{"date":"2023-12-31","value":-179.89,"profit":false},{"date":"2024-12-31","value":21.56,"profit":true}]
EPS (Diluted)1.69(1.15)(3.03)(2.16)(0.75)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-68.05,"profit":false},{"date":"2022-12-31","value":-179.29,"profit":false},{"date":"2023-12-31","value":-127.81,"profit":false},{"date":"2024-12-31","value":-44.38,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

CHRS
Cash Ratio 0.45
Current Ratio 1.24
Quick Ratio 0.84

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CHRS
ROA (LTM) -10.94%
ROE (LTM) -1657.06%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CHRS
Debt Ratio Lower is generally better. Negative is bad. 1.29
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.29

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CHRS
Trailing PE 4.12
Forward PE 41.15
P/S (TTM) 0.45
P/B 73.19
Price/FCF 4
EV/R 0.99
EV/Ebitda 4.32
PEG NM

FAQs

What is Coherus BioSciences Inc share price today?

Coherus BioSciences Inc (CHRS) share price today is $1.03

Can Indians buy Coherus BioSciences Inc shares?

Yes, Indians can buy shares of Coherus BioSciences Inc (CHRS) on Vested. To buy Coherus BioSciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CHRS stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Coherus BioSciences Inc be purchased?

Yes, you can purchase fractional shares of Coherus BioSciences Inc (CHRS) via the Vested app. You can start investing in Coherus BioSciences Inc (CHRS) with a minimum investment of $1.

How to invest in Coherus BioSciences Inc shares from India?

You can invest in shares of Coherus BioSciences Inc (CHRS) via Vested in three simple steps:

  • Click on Sign Up or Invest in CHRS stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Coherus BioSciences Inc shares
What is Coherus BioSciences Inc 52-week high and low stock price?

The 52-week high price of Coherus BioSciences Inc (CHRS) is $2.43. The 52-week low price of Coherus BioSciences Inc (CHRS) is $0.66.

What is Coherus BioSciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Coherus BioSciences Inc (CHRS) is 4.12

What is Coherus BioSciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Coherus BioSciences Inc (CHRS) is 73.19

What is the Market Cap of Coherus BioSciences Inc?

The market capitalization of Coherus BioSciences Inc (CHRS) is $122.85M

What is Coherus BioSciences Inc’s stock symbol?

The stock symbol (or ticker) of Coherus BioSciences Inc is CHRS

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top